TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

por Jørgensen, Charlotte Levin Tykjær, Bjerre, Christina, Ejlertsen, Bent, Bjerre, Karsten D, Balslev, Eva, Bartels, Annette, Brünner, Nils, Nielsen, Dorte L
Publicado 2014

Exome sequencing identifies somatic point mutations associated with acquired endocrine resistance in breast cancer cell lines

por Ehlers, Natasja S, Da, Zhu Shi, Elias, Daniel, Lin, Xue, Li, Jian, Bjerre, Christina, Brunner, Nils, Bolund, Lars, Jun, Wang, Gupta, Ramneek, Ditzel, Henrik J
Publicado 2012

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial

por Røssevold, Andreas Hagen, Andresen, Nikolai Kragøe, Bjerre, Christina Annette, Gilje, Bjørnar, Jakobsen, Erik Hugger, Raj, Sunil Xavier, Falk, Ragnhild Sørum, Russnes, Hege Giercksky, Jahr, Thea, Mathiesen, Randi Ruud, Lømo, Jon, Garred, Øystein, Chauhan, Sudhir Kumar, Lereim, Ragnhild Reehorst, Dunn, Claire, Naume, Bjørn, Kyte, Jon Amund
Publicado 2022

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

por Løkkegaard, Sanne, Elias, Daniel, Alves, Carla L., Bennetzen, Martin V., Lænkholm, Anne-Vibeke, Bak, Martin, Gjerstorff, Morten F., Johansen, Lene E., Vever, Henriette, Bjerre, Christina, Kirkegaard, Tove, Nordenskjöld, Bo, Fornander, Tommy, Stål, Olle, Lindström, Linda S., Esserman, Laura J., Lykkesfeldt, Anne E., Andersen, Jens S., Leth-Larsen, Rikke, Ditzel, Henrik J.
Publicado 2021